Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Hold Alembic Pharma; target of Rs 540: ICICI Direct

ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 540 in its research report dated July 30, 2019.

July 31, 2019 / 04:18 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct's research report on Alembic Pharma

Revenues grew 10% YoY to Rs 949 crore (I-direct estimate: Rs 980 crore) due to 53% YoY growth in US to Rs 345 crore (I-direct estimate: Rs 317 crore). Domestic formulations declined 2.1% to Rs 324 crore (I-direct estimate: Rs 374 crore). EBITDA margins improved 620 bps YoY to 23.7% (I-direct estimate: 19.0%) mainly due improvement in gross margins (78.5% vs. 70.4% in Q1FY19). EBITDA grew 49% YoY to Rs 224.9 crore vis-à-vis I-direct estimate of Rs 186.2 crore. Net profit grew 27.4% YoY to Rs 115.2 crore (I-direct estimate of Rs 119.3 crore) mainly due to a strong operational performance.

Outlook

The benefits are most likely to be back-loaded. Immediate cash burn is likely to weigh on sentiments in the near term. Our target price arrives at Rs 540 based on 22x FY21E EPS of Rs 25.4.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Jul 31, 2019 04:18 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347